This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of CNCT19 cell injection in the treatment of patients with relapsed/refractory Neurological Autoimmune Diseases.
Patients who are willing to sign the informed consent form;
Aged 18-75 years, male or female;
aquaporin 4 (AQP4) -IgG positive
At least one immunosuppressant has been used for more than one year and the symptoms have not been well controlled;
Current medical conditions or neurological disorders that may affect the effectiveness assessment, such as dementia, schizophrenia, bipolar disorder, major depressive disorder, history of multiple traumatic brain injury, current alcohol/drug abuse or dependence, or alcohol/drug dependence within the past two years.
Pregnancy or breastfeeding;
Have received organ or hematopoietic stem cell transplantation in the past;
There has been a history of new thrombosis or organ infarction within the past six months;
Single group
CNCT19 cell injection
Biological/VaccineA conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
Number of participants with dose-limiting toxicities (DLTs)
Number of participants with adverse events (AEs)/serious adverse events (SAEs)
Number of participants with disability improvement confirmed per EDSS
NMOSD、MOGAD
Annualized relapse rate
NMOSD、MOGAD、MS
Change from baseline in magnetic resonance imaging (MRI) metrics
NMOSD、MOGAD：MRI metrics assessed is number of gadolinium-enhancing T1 lesions.
Change from baseline in magnetic resonance imaging (MRI) metrics
NMOSD、MOGAD：MRI metrics assessed is total number of new or enlarging hyperintense T2-weigted lesions.
Click on the lead sponsor to view all of their trials.
Juventas Cell Therapy Ltd.
Lead sponsor
Beijing Tiantan Hospital
Collaborator
